UBS O'Connor’s Larimar Therapeutics LRMR Stock Holding History

UBS O'Connor’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-40,000	Closed	-$2K	–	595
2024 Q1	$2K	Buy	+40,000	New	+$312K	﹤0.01%	508

Other funds holding LRMR

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

UBS O'Connor's LRMR Position: Q3 2025 in Review

UBS O'Connor sold out of Larimar Therapeutics (LRMR) in Q3 2025, closing a stake of 307,198 shares — an estimated $888K sold.

UBS O'Connor first reported a position in LRMR in Q1 2015 and held it in 12 quarters. The position peaked at $2.78M in Q2 2015. 136 funds tracked by Wall St. Rank hold LRMR as of Q3 2025.

UBS O'Connor reported no remaining Larimar Therapeutics position as of Q3 2025 after selling out during the quarter.
UBS O'Connor sold 307,198 Larimar Therapeutics shares in Q3 2025, an estimated $888K.
UBS O'Connor first reported a position in Larimar Therapeutics in Q1 2015 and held it in 12 quarters.
UBS O'Connor's Larimar Therapeutics position peaked at $2.78M in Q2 2015.
136 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.